Cargando…

COVID-19 Vaccination Strategy in China: A Case Study

The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 Novem...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamadi, Marjan, Lin, Yuling, Vulliet, Mélissa Vuillet Soit, Flahault, Antoine, Rozanova, Liudmila, Fabre, Guilhem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620874/
https://www.ncbi.nlm.nih.gov/pubmed/36417234
http://dx.doi.org/10.3390/epidemiologia2030030
_version_ 1784821412700094464
author Mohamadi, Marjan
Lin, Yuling
Vulliet, Mélissa Vuillet Soit
Flahault, Antoine
Rozanova, Liudmila
Fabre, Guilhem
author_facet Mohamadi, Marjan
Lin, Yuling
Vulliet, Mélissa Vuillet Soit
Flahault, Antoine
Rozanova, Liudmila
Fabre, Guilhem
author_sort Mohamadi, Marjan
collection PubMed
description The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with 483.34 million doses having been administered across the country by 21 May 2021. China is also acting as an important player in the development and production of SARS-CoV-2 vaccines.
format Online
Article
Text
id pubmed-9620874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96208742022-11-18 COVID-19 Vaccination Strategy in China: A Case Study Mohamadi, Marjan Lin, Yuling Vulliet, Mélissa Vuillet Soit Flahault, Antoine Rozanova, Liudmila Fabre, Guilhem Epidemiologia (Basel) Article The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with 483.34 million doses having been administered across the country by 21 May 2021. China is also acting as an important player in the development and production of SARS-CoV-2 vaccines. MDPI 2021-09-03 /pmc/articles/PMC9620874/ /pubmed/36417234 http://dx.doi.org/10.3390/epidemiologia2030030 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mohamadi, Marjan
Lin, Yuling
Vulliet, Mélissa Vuillet Soit
Flahault, Antoine
Rozanova, Liudmila
Fabre, Guilhem
COVID-19 Vaccination Strategy in China: A Case Study
title COVID-19 Vaccination Strategy in China: A Case Study
title_full COVID-19 Vaccination Strategy in China: A Case Study
title_fullStr COVID-19 Vaccination Strategy in China: A Case Study
title_full_unstemmed COVID-19 Vaccination Strategy in China: A Case Study
title_short COVID-19 Vaccination Strategy in China: A Case Study
title_sort covid-19 vaccination strategy in china: a case study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620874/
https://www.ncbi.nlm.nih.gov/pubmed/36417234
http://dx.doi.org/10.3390/epidemiologia2030030
work_keys_str_mv AT mohamadimarjan covid19vaccinationstrategyinchinaacasestudy
AT linyuling covid19vaccinationstrategyinchinaacasestudy
AT vullietmelissavuilletsoit covid19vaccinationstrategyinchinaacasestudy
AT flahaultantoine covid19vaccinationstrategyinchinaacasestudy
AT rozanovaliudmila covid19vaccinationstrategyinchinaacasestudy
AT fabreguilhem covid19vaccinationstrategyinchinaacasestudy